1. Prevalence of Dementia With Lewy Body Symptoms: A Cross-Sectional Study in 40 Swedish Nursing Homes.

    Journal of the American Medical Directors Assoc... 17(8):706 (2016) PMID 27168051

    To investigate and establish the prevalence of dementia with Lewy body (DLB) symptoms in all nursing home (NH) residents in Malmö, the third largest city in Sweden. DLB is a neurocognitive disorder with core features, such as parkinsonism, visual hallucinations, and fluctuating cognition/excessi...
  2. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.

    Neurology 86(19):1754 (2016) PMID 27164711 PMCID PMC4862247

    We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity. In...
  3. Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease.

    Journal of Alzheimer's Disease 52(3):1047 (2016) PMID 27079711

    Copeptin is a reliable surrogate marker for the neurohypophyseal hormone vasopressin. Elevated plasma level of copeptin has been associated with cardiovascular and metabolic disease risk. To investigate the association between copeptin and risk of dementia. In all, 18,240 individuals from Malmö,...
  4. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

    Annals of clinical and translational neurology 3(3):154 (2016) PMID 27042676 PMCID PMC4774260

    The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) must be improved before widespread clinical use. This study aimed to determine whether CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios are better diagnostic biomarkers of AD during both predementia and dementia stage...
  5. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.

    Alzheimer's & Dementia 12(2):154 (2016) PMID 26368321

    Lumbar puncture (LP) is increasingly performed in memory clinics. We investigated patient-acceptance of LP, incidence of and risk factors for post-LP complications in memory clinic populations. We prospectively enrolled 3868 patients (50% women, age 66 ± 11 years, mini mental state examination 2...
  6. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

    Alzheimer's Research & Therapy 8(1):17 (2016) PMID 27121148 PMCID PMC4848774

    Alzheimer's disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to late-onset AD and other neurodegenerative disorders. TREM2, a microglial rec...
  7. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.

    Alzheimer's Research & Therapy 8(1):7 (2016) PMID 26883213 PMCID PMC4756534

    There is an increasing interest in cognitive and functional outcomes in the respective stages of Alzheimer's disease (AD) and in novel therapies particularly for the milder phases of AD. Our aim was to describe and compare various aspects of disease progression in patients with mild versus moder...
  8. Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

    Nature Communications 7:10918 (2016) PMID 26948379 PMCID PMC4786682

    Increased APP (amyloid precursor protein) processing causes β-amyloid (Aβ) accumulation in autosomal dominant Alzheimer's disease (AD), but it is unclear if it also affects sporadic Aβ accumulation. We tested healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER stu...
  9. Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.

    Scientific reports 6:20709 (2016) PMID 26856756 PMCID PMC4746584

    Small vessel disease (SVD) and amyloid deposition may promote each other, with a potential association between SVD and altered production or clearance of β-amyloid (Aβ) affecting its cleavage products. We investigated the relationship between SVD, multiple isoforms of Aβ in cerebrospinal fluid (...
  10. Reliability, validity and clinical correlates of the Quality of Life in Alzheimer's disease (QoL-AD) scale in medical inpatients.

    Health and Quality of Life Outcomes 14(1):90 (2016) PMID 27301257 PMCID PMC4908755

    There is a lack of standardisation in quality of life (QoL) measurements to be used in older multimorbid patients. An ideal QoL measurement should be reliable, valid, subjective, multidimensional, feasible and generic. We hypothesised that the QoL-AD (Quality of Life in Alzheimer's Disease) scal...
  11. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study.

    Alzheimer's & dementia : diagnosis, assessment ... 1(4):403 (2015) PMID 27239521 PMCID PMC4879483

    Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials. In this prospective longitudinal study, repeated cerebrospinal fluid (...
  12. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study.

    Alzheimer's & Dementia 11(11):1306 (2015) PMID 25804998

    The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ1-42), phosphorylated tau, and total tau (tau) to discriminate Alzheimer's disease (AD) dementia from other forms of dementia. A total of 675 CSF samples collected at eight memory clinics were obt...
  13. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.

    Neurology 85(14):1240 (2015) PMID 26354982 PMCID PMC4607601

    To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD). From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI...
  14. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

    Alzheimer's & Dementia 11(10):1180 (2015) PMID 25533203

    Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. Consequently, synaptic biomarkers may be valuable tools for both early diagnosis and disease stage. Neurogranin (Ng) is a postsynaptic protein involved in memory consolid...
  15. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

    Journal of Proteome Research 14(2):654 (2015) PMID 25490617

    Many disease processes in the brain are reflected in the protein composition of the cerebrospinal fluid (CSF). In addition to proteins, CSF also contains a large number of endogenous peptides whose potential as disease biomarkers largely remains to be explored. We have developed a novel workflow...
  16. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.

    Dementia and Geriatric Cognitive Disorders 40(5-6):297 (2015) PMID 26335053

    Factors including rate of disease progression, different aspects of cholinesterase inhibitor (ChEI) treatment, and use of community-based services might affect the longitudinal outcome of Alzheimer's disease (AD). Whether these factors alter life expectancy in AD is unclear. We therefore examine...
  17. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.

    Alzheimer's Research & Therapy 7(1):40 (2015) PMID 26136856 PMCID PMC4487851

    Synaptic dysfunction and degeneration are central events in Alzheimer's disease (AD) pathophysiology that are thought to occur early in disease progression. Synaptic pathology may be studied by examining protein biomarkers specific for different synaptic elements. We recently showed that the den...
  18. Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index.

    Current Alzheimer Research 12(1):69 (2015) PMID 25523428

    We evaluated the performance of the Disease State Index (DSI) method when predicting progression to Alzheimer's disease (AD) in patients with subjective cognitive impairment (SCI), amnestic or non-amnestic mild cognitive impairment (aMCI, naMCI). The DSI model measures patients' similarity to di...
  19. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.

    PLoS ONE 10(8):e0135458 (2015) PMID 26270969 PMCID PMC4536228

    A major difference in the revised diagnostic criteria for Alzheimer's disease (AD) is the incorporation of biomarkers to support a clinical diagnosis and allow the identification of preclinical AD due to AD neuropathological processes. However, AD-specific fluid biomarkers which specifically dis...
  20. Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness.

    Cerebrovascular Diseases Extra 5(2):41 (2015) PMID 26120319 PMCID PMC4478329

    Arterial stiffness reflects the ageing processes in the vascular system, and studies have shown an association between reduced cognitive function and cerebral small vessel disease. Small vessel disease can be visualized as white matter hyperintensities (WMH) and lacunar infarcts but also as cere...